Fenfluramine HCl (Fintepla^®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

Abstract

Study results demonstrate that fenfluramine provides clinically meaningful (≥50%) seizure frequency reduction over an extended period in patients with Dravet syndrome. No patient developed VHD or PAH, and fenfluramine was generally well tolerated.